Tag Archive for: oncology

Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

/in

RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part by MRC grant Poolbeg will act as the lead business partner alongside Johnson & Johnson and other partners 8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that […]

Read more

Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer

/in

Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape Brings over 15 years of global oncology and hematology leadership, advancing over 10 radioligands across the development spectrum, from preclinical to Phase III   Oslo, Norway and Cambridge, Massachusetts — 3 December 2025 — […]

Read more

Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar

/in

Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractory multiple myeloma. R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST) Ladenburg, Germany, 3 […]

Read more

Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors

/in

DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody Differentiated binding capacities and competitive properties position it as a promising therapeutic to boost anti-tumor immunity, overcoming immunosuppression Strasbourg, France – Montreal, Canada – Boston, United States, October 28, 2025: Domain Therapeutics ( “Domain” or “the Company” ), the GPCR experts harnessing deep receptor biology to develop […]

Read more

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma

/in

Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs Enables more frequent engagement with FDA and eligibility for rolling review to support expedited development and review Ladenburg, Germany, 23 October 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), […]

Read more